# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and

14	CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form
	Mobile Health Interventions  J Med Internet Res 2011;13(4):e126  URL: <a href="http://www.jmir.org/2011/4/e126/">http://www.jmir.org/2011/4/e126/</a> doi: 10.2196/jmir.1923
	PMID: 22209829
	* Required
	Your name *
	First Last
	Robert Morris
	Primary Affiliation (short), City, Country *
	University of Toronto, Toronto, Canada
	MIT Media Lab
	Your e-mail address *
	abc@gmail.com
	rmorris@media.mit.ed
	Title of your manuscript *
	Provide the (draft) title of your manuscript.
	Efficacy of a Web-Based, Peer-To-Peer Cognitive Reappraisal Platform: a Randomized Controlled Trial
	Article Preparation Status/Stage *
	At which stage in your article preparation are you currently (at the time you fill in this form)
	onot submitted yet - in early draft status
	o not submitted yet - in late draft status, just before submission
	submitted to a journal but not reviewed yet
	submitted to a journal and after receiving initial reviewer comments
	submitted to a journal and accepted, but not published yet

Journal \*

Other:

published

If you already know where you will submit this paper (or if it is already submitted), please provide the

#### Does your paper address subitem 1a-i?\*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information

not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Efficacy of a Web-Based, Peer-To-Peer Cognitive Reappraisal
Platform: a Randomized Controlled Trial"

#### 1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Efficacy of a Web-Based, Peer-To-Peer Cognitive Reappraisal Platform: a Randomized Controlled Trial"

#### 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes")

Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes:

Randomized Controlled Trial

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 1a-iii? \*


"Efficacy of a Web-Based, Peer-To-Peer Cognitive Reappraisal Platform: a Randomized Controlled Trial"

# 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

### 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-i?\*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants, aged 18-35, were recruited online and were randomly assigned to the treatment group (Panoply, n=84) or an active control group (online expressive writing, n=82), both of which were fully automated web-based platforms. Participants were asked to use their assigned platform for a minimum of 25-minutes per week for three weeks. Both platforms involved posting descriptions of stressful thoughts and situations. Participants on the Panoply platform additionally received crowdsourced reappraisal support immediately

#### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

subitem not at all important	$\bigcirc$	$\bigcirc$	ullet	$\bigcirc$	$\bigcirc$	essential

#### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"both of which were fully automated web-based platforms."

### 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	ı	2	3	4	5	
subitem not at all important		0	0	•	$\bigcirc$	essential

#### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

weeks. Both platforms involved posting descriptions of stressful thoughts and situations. Participants on the Panoply platform additionally received crowdsourced reappraisal support immediately after submitting a post (median response time = 9 minutes). Panoply participants were also given the opportunity to practice reappraising stressful situations submitted by other users. Online questionnaires administered at baseline and three weeks assessed depression symptoms (CES-D), reappraisal (ERQ-R), and perseverative thinking


#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing

from the main body of text,	cons	side	r ad	ding	it)	
	1	2	3	4	5	
subitem not at all important	0	$\bigcirc$	0	•		essential


#### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Panoply engaged its users and was especially helpful for depressed individuals and for those who might ordinarily underutilize reappraisal techniques. Further investigation is needed to examine the long-term effects of such a platform and whether the benefits generalize to a more diverse population of users."


#### INTRODUCTION

### 2a) In INTRODUCTION: Scientific background and

### explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)



#### Does your paper address subitem 2a-i? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Mixed findings with regard to discussion forums and peer-to-peer support applications is not surprising given the lack of oversight on the content provided in these resources.

Still, there may be a way to adapt these platforms, creating peer-to-peer interactions that are structured and moderated to reinforce evidence-based clinical techniques. It may be possible, for instance, to create an intervention that is as engaging and personalized as typical peer-to-peer platforms, while still providing the therapeutic

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



#### Does your paper address subitem 2a-ii? \*

many self-guided interventions suffer from high attrition rates and low levels of engagement. A recent review of self-guided, web-based treatments found a median completion rate of 56% [6]. Open trials show even higher rates of attrition [7]. Low levels of engagement can be especially problematic and might be one of the reasons that self-guided treatments produce smaller gains than supported methods [4]...there remains a paucity of rigorous, controlled studies on the efficacy of online support groups and peer-to-peer support

# 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In this paper we examine the hypotheses that repeated use of this platform will reduce depression symptoms and that the social, interactive design will promote engagement."

#### **METHODS**

# 3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We conducted a parallel-arm randomized controlled trial (RCT), assigning participants to either the Panoply intervention or an active control intervention (online expressive writing)...Participants who submitted their emails were assigned unique, anonymous study IDs and were randomized to condition on a 1-to-1 ratio."

### 3b) Important changes to methods after trial

## commencement (such as eligibility criteria), with reasons

#### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes.			
			1

#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	$\bigcirc$	•	$\bigcirc$	$\bigcirc$	essential

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No content changes.	
	1

### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

"To be eligible for the trial, participants needed to be native Eng speakers between the ages of 18 and 35."	lish

#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This age range was selected because users in this age group are more likely to have experience with anonymous, social messaging platforms, and this study sought to find initial support for this platform rather than investigating widespread implementation."

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.


1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 4a-ii? \*

websites (craigslist, research portals), and through social media channels (Facebook, Twitter). Participants signed up on the web, by submitting their emails on the study recruitment website...Though all study procedure emails were automated, participants could email the experimenters directly during the study if they needed clarifications about the procedures or if they had technical difficulties using their assigned application...It was open to the general public and depression status was not an inclusion criterion."

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study was advertised as an opportunity to try a new, web-based stress reduction application. It was open to the general public and depression status was not an inclusion criterion."

## 4b) Settings and locations where the data were collected

#### Does your paper address CONSORT subitem 4b? \*

"The online assessments were hosted by SurveyGizmo." Behavioral
data from the platform was logged on our servers.

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

#### Does your paper address subitem 4b-i?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The online assessments were hosted by SurveyGizmo and required a unique studyID to login."

#### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)

1 2 3 4 5
subitem not at all important O O essential

#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The social media advertisements were broadcast from MIT's Media Lab, which is has a reputation for high tech innovation, and it is likely that this recruiting channel attracted tech-curious individuals who were not actually in need of an intervention."

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

#### 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

1 2 3 4 5
subitem not at all important \( \) \( \) \( \) \( \) \( \) essential

#### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Panoply is a peer-to-peer, web-based cognitive reappraisal program developed at the MIT Media Lab."

#### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

and over the web. For lab-based studies, an experimenter was present at all times and the sessions were moderated using techniques such as 'concurrent thinking aloud', 'retrospective thinking aloud', and 'retrospective probing' [41]. MTurk workers were also recruited online to help identify potential design flaws. These studies helped identify user experience issues and points of confusion around site navigation and other user interface components (e.g., buttons, links), enabling us to refine the usability before the RCT was

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial.

Describe dynamic components such as news feeds or changing content which may have an impact on
the replicability of the intervention (for unexpected events see item 3b).

1 2 3 4 5
subitem not at all important O O essential

#### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



#### 5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


No.

## 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

1 2 3 4 5

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form
subitem not at all important 🔘 🔘 💿 essential
Does your paper address subitem 5-v?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
Figures 2-4. Previous design work related to this platform is also cited.
<b>5-vi) Digital preservation</b> Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, webcitation.org, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.
1 2 3 4 5
subitem not at all important O O essential
Does your paper address subitem 5-vi?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  The URL requires a login and password, but guest accounts are available upon request. Figures 2-4 illustrate elements of the system design. Previous design work related to this platform is also cited.



#### 5-vii) Access


Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 2 3 4 5

subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	ullet	$\bigcirc$	essential

#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



## 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	ı	2	3	4	5	
subitem not at all important	0	$\bigcirc$	$\bigcirc$	•	0	essential

#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

efficacious intervention it its own right and can help reduce depression symptoms [39]. A meta-analysis has found expressive writing in various applications can improve physical and psychological health outcomes [40]. This condition was a useful control because although it matched Panoply on nonspecific factors (e.g., web design, user registration, composing negative thoughts), it did not contain reappraisal training or crowdsourced interactions. However, it did allow users to engage in a similar process of entering content, thus

#### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"After completing the consent form and baseline assessments, participants were asked to use their studyIDs to create an anonymous account on their assigned platform. They were told to use the application for at least 25-minutes per week, for three weeks. To best approximate real usage with an unmoderated application, participants were not given any further instructions about how to use their assigned system. Instead, participants were told to use the application in ways that best fit their schedules and interests."

#### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Though all study procedure emails were automated, participants could email the experimenters directly during the study if they needed clarifications about the procedures or if they had technical difficulties using their assigned application. To be able to answer specific questions about either the control or treatment application, experimenters were not blind to the random assignment of participants. However, during the course of the study, only four participants emailed the experimenters to request technical support

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	ı	2	3	4	5	
subitem not at all important	0	0	•	0	0	essential

#### Does your paper address subitem 5-xi?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To best approximate real usage with an unmoderated application, participants were not given any further instructions about how to use their assigned system. Instead, participants were told to use the application in ways that best fit their schedules and interests. Participants in both groups received four automated emails throughout the study reminding them to use their assigned application."

#### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	•	0	$\bigcirc$	essential

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no co-interventions.	

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants completed assessments online, both at baseline and at 3-weeks' follow-up. The primary outcome measure was the CES-D [42], a 20-item self-report scale that assesses symptoms of depression. Secondary outcome measures included reappraisal frequency, as assessed by the ERQ-R [24], and maladaptive rumination, as assessed by the PTQ [43]."

## 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

"The online assessments were hosted by SurveyGizmo and required a unique studyID to login. This prevented multiple submissions. Incomplete survey data was not included in the analyses."

### 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers

was addressed


## 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

1 2 3 4 5
subitem not at all important ( ) ( ) ( ) essential

#### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



# 7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable.			

## 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to

indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization and email correspondence were automatically
coordinated through scripts we wrote in the Python programming
language."

# 8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants who submitted their emails were assigned unique, anonymous study IDs and were randomized to condition on a 1-to-1 ratio. Randomization occurred prior to any screening procedures and before participants received descriptions of their assigned intervention in the consent form."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization and email correspondence were automatically coordinated through scripts we wrote in the Python programming language... Participants who submitted their emails were assigned unique, anonymous study IDs and were randomized to condition on a 1-to-1 ratio."

# 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

#### Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Randomization and email correspondence were automatically coordinated through scripts we wrote in the Python programming language... Participants who submitted their emails were assigned unique, anonymous study IDs and were randomized to condition on a 1-to-1 ratio."

# 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Though all study procedure emails were automated, participants could email the experimenters directly during the study if they needed clarifications about the procedures or if they had technical difficulties using their assigned application. To be able to answer specific questions about either the control or treatment application, experimenters were not blind to the random assignment of participants. However, during the course of the study, only four participants emailed the experimenters to request technical support

### 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

	1	2	3	4	5	
subitem not at all important	0	$\bigcirc$	$\bigcirc$	•	$\bigcirc$	essentia

#### Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

approach also prevented our control participants from feeling unmotivated, simply because they felt they had been assigned a less exciting, less social application. With this approach, we were less likely to encounter the 'resentful moralization problem' - a bias that can occur when consent is provided prior to randomization [32], [33]. Because of these benefits, and because both our control and treatment interventions had active, putative mechanisms for therapeutic effects, our randomization procedure was deemed

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The visual and interface design for the control condition was built to
mirror the Panoply intervention. The instructions for describing stressful
situations and negative thoughts were exactly the same (Figure 4)."

# 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

#### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

specific moderators and mediators. Since Panoply was designed to teach reappraisal skills, we hypothesized that Panoply would result in greater improvements for those with deficits in this skill (as measured by reappraisal on the ERQ at baseline) and we posited that reappraisal might be a useful mechanism of action within the Panoply condition. Our primary analyses compared the difference between the groups at post-test using linear regression models controlling for baseline levels of the dependent measure."

#### 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

#### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No. There were only two time points used in this study, so imputation techniques were not appropriate.

# 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

#### Does your paper address CONSORT subitem 12b? \*

higher as depressed. For reappraisal, participants were dichotomized into two groups (high and low reappraisers) based on a median split. We examined mediation using Preacher and Hayes (2008) bootstrapping procedure and SPSS macro. This procedure produces the bias-corrected and accelerated bootstrapped confidence intervals of the product of the direct pathways between condition and the mediator (a) and the mediator and the outcome (b) to estimate the indirect effect (ab). "

# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study was approved by the MIT Committee on the Use of Human Subjects as Experimental Subjects (ref. no. 1311006002)"

#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.


1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem X26-ii?

approach also prevented our control participants from feeling unmotivated, simply because they felt they had been assigned a less exciting, less social application. With this approach, we were less likely to encounter the 'resentful moralization problem' - a bias that can occur when consent is provided prior to randomization [32], [33]. Because of these benefits, and because both our control and treatment interventions had active, putative mechanisms for therapeutic effects, our randomization procedure was deemed

#### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)



#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"...crowd helpers from Amazon's Mechanical Turk service (MTurk) are hired to review each post. Any post that contains offensive material, off-topic content, or language related to self-harm is excluded from the system. In the case of language related to self-harm, an automated email is immediately sent to the author of the post. The email includes links to mental health resources and reminds the poster that the system is a self-help tool, not to be used for crisis-related situations... Responses are vetted by other crowd

### **RESULTS**

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

Figure 1. Consort Flow diagram	

# 13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

were broadcast from MIT's Media Lab, which is has a reputation for high tech innovation, and it is likely that this recruiting channel attracted tech-curious individuals who were not actually in need of an intervention. It is likely that others dropped out for similar reasons. Other reasons for drop out included not having enough time to adhere to the recommended 25/min per week guidelines (n=2), being out of town (n=1), or not having reliable access to a desktop computer (n=1). The remaining 41 individuals who did not activate an account could not be reached for comment and did not respond to

#### 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

#### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Figure 1. Consort Flow diagram

# 14a) Dates defining the periods of recruitment and follow-up

#### Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Recruitment took place between April and June of 2014."	
	/

#### 14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

	1	2	3	4	5	
subitem not at all important	0	0	•	0	0	essentia

#### Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No "secular events."	

### 14b) Why the trial ended or was stopped (early)

#### Does your paper address CONSORT subitem 14b? \*

Not applicable.

# 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1.		

#### 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important		$\bigcirc$	•	$\bigcirc$		essentia

#### Does your paper address subitem 15-i?\*

Table 1.		
		//

# 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

#### 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Numbers are shown in Table 1.

#### 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Since we only had two time points and some participants were lost to follow-up, intent-to-treat analysis was not appropriate: "All participants who completed follow-up assessments were included in the analyses (whether they used their assigned platform or not). Some participants, however, were lost to follow-up and were not included in the analysis of outcome. As only two assessment time points were obtained, methods of data imputation would be inappropriate."

# 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

#### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

reappraisal (a) was statistically significant (B = .39, SE = .16, P = .02, 95% CI .08, .70). The effect of change in reappraisal on change in depression (b) was also statistically significant (B = -2.55, SE = .63, P < .001, 95% CI -3.78, -1.32 ). The indirect effect of Panoply on changes in depression via changes in reappraisal was statistically significant (ab = -1.04, SE = .58, 95% CI -2.67, -.12). These results suggest that change in reappraisal may be a specific mechanism of Panoply compared to the writing condition in reducing depressive

#### 17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

1 2 3 4 5
subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 17a-i?

users in the Panoply condition logged 21 sessions over the three-week deployment on average. Their average time per session was 9 minutes and 18 seconds per session. By comparison, users in the expressive writing condition logged an average of 10 sessions, spending an average of 3 minutes and 10 seconds per session. Thus, the Panoply group averaged a total of over 195 minutes over the course of the study, a considerably longer amount than was suggested (75 minutes). Inferential statistics could not be computed,

## 17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

#### Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, dropout rates were not significantly different. Module adherence, a commonly used metric, was not relevant for this study.	

# 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

#### Does your paper address CONSORT subitem 18?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

١	Yes, we performed mediation and moderation analyses.
	· ·
	//

#### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	ı	2	3	4	5	
subitem not at all important	0	•	0	0	0	essential

#### Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.			
			- /

# 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

#### Does your paper address CONSORT subitem 19?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

an automated email was sent, reminding the participant that Panoply is a self-help tool, not a formal mental health resource. Links to mental health resources were also emailed automatically to this participant. After consulting with the MIT IRB, we decided to prevent this participant from posting any further content. This individual was not withdrawn from the study, however, and was still allowed to compose responses. None of the responses this individual made to others were flagged as off-topic, malicious, or otherwise

#### 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5	
subitem not at all important		$\bigcirc$	$\bigcirc$	•		essentia

#### Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to

indicate direct quotes from your manuscript), or elaboration in the ms, or briefly explain why the item is not ap	, ,
Not applicable.	
19-ii) Include qualitative feedback from particip	ants or observations from staff/researchers
Include qualitative feedback from participants or obs strengths and shortcomings of the application, espec- oruses. This includes (if available) reasons for why re-	cially if they point to unintended/unexpected effects

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	•	$\bigcirc$	$\bigcirc$	essentia

#### Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No.		
		/

#### **DISCUSSION**

by the developers.

# 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study guestions and summarize the answers suggested by the data, starting with primary

#### Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

to regulate emotions. Panoply was engineered to be an engaging mental health intervention. The final system incorporated many features that were specifically designed to enhance user experience. Indeed, it was hoped that many users would find the crowdsourced interactions particularly novel, motivating, and exciting. Therefore, it was hypothesized that Panoply would score higher on both self-reported user experience and behavioral measures of activity, relative to the expressive writing condition. These hypotheses were

#### 22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

time, it is unclear how enduring these improvements might be. Additional long-term follow-ups are needed. Also, the study was limited to individuals aged 18-35. Additional research is needed to examine whether similar effects might be observed for other populations of users. Our sample was also largely female and future studies will need to seek a more balanced gender distribution. Moreover, while expressive writing was a useful control comparison for many reasons, future studies should compare Panoply to more

# 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

#### 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look

at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

should address other techniques besides just cognitive reappraisal. For instance, Panoply could be extended to address some of the behavioral components of CBT. Behavioral interventions from positive psychology could also be incorporated in future versions, as described by Morris & Picard [30]. Finally, all interactions with Panoply were made through a web browser, optimized for use on a laptop or desktop. To increase engagement, the platform could be redesigned for mobile use, to better align with contemporary

### 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

#### 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

should address other techniques besides just cognitive reappraisal. For instance, Panoply could be extended to address some of the behavioral components of CBT. Behavioral interventions from positive psychology could also be incorporated in future versions, as described by Morris & Picard [30]. Finally, all interactions with Panoply were made through a web browser, optimized for use on a laptop or desktop. To increase engagement, the platform could be redesigned for mobile use, to better align with contemporary

### 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In a routine application, there would likely be less involvement with MTurk workers. Otherwise, the application could be used exactly as is described.

#### OTHER INFORMATION

### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

ClinicalTrials.gov NCT02302248

## 24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

ClinicalTrials.gov		
		,

# 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Funding came from the MIT Media Lab member consortium. Dr. Schueller was supported by a grant from the National Institute of Mental Health K08 MH102336 (PI: Schueller).

### X27) Conflicts of Interest (not a CONSORT item)

#### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	ı	2	3	4	5	
subitem not at all important	0	$\bigcirc$	•	0	$\bigcirc$	essential

#### Does your paper address subitem X27-i?

"Drs. Picard and Schueller have no conflicts of interest. Morris had no conflicts of interest at the time of developing Panoply, conducting the RCT, and analyzing the results. Since the work was completed, Dr. Morris has taken preliminary steps towards forming a company related to peer-produced mental health interventions."

#### About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript?*
O yes, major changes
yes, minor changes
○ no
What were the most important changes you made as a result of using this checklist?
Considerable changes were made to the format and content of the abstract.
How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *  3hrs
As a result of using this checklist, do you think your manuscript has improved? *
• yes
○ no
Other:
Would you like to become involved in the CONSORT EHEALTH group?  This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
○ yes
<ul><li>no</li></ul>
Other:

Any other comments or questions on CONSORT EHEALTH



### STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

### Final step: Click submit!

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

Powered by

This content is neither created nor endorsed by Google.

Report Abuse - Terms of Service - Additional Terms